MAPP research network MAPP II SPS	**Participant ID:** __ __ __ __ __ __	**Pin #**	__ __ __ __
	Discovery Site: __ __	**Clinical Center**	__ __
	CRF Date: __ __/__ __/__ __ __ __	**Visit #:**	__ __

MAPP Phase II Eligibility Confirmation for Control Participants

Research Coordinator completes at **Month 0 and Month 6 Screening/Deep Phenotyping** Clinic Contacts.

1.	Control Participant has signed and dated the appropriate Informed Consent document and has agreed to participate in ***ALL*** required **Controls Protocol** procedures (including **Biospecimen collections**, **MAPP Pelvic Exam**, **Neuroimaging**, and **Quantitative Sensory Testing**).	❑$_1$ Yes	❑$_0$ No
	a. If **Yes**, record date the form was signed	__ __/__ __/__ __ __ __ (MM DD YYYY)	
	b. Did the Control Participant give permission for use of DNA for genetics studies? (Answer to 1b ***MUST*** be ***Yes*** for Participant to be eligible.)	❑$_1$ Yes	❑$_0$ No
2.	Participant gender:	❑$_1$ Male	❑$_2$ Female
3.	Participant is ≥ 18 years of age.	❑$_1$ Yes	❑$_0$ No
4.	Participant is able to speak, read, and understand English.	❑$_1$ Yes	❑$_0$ No

Inclusion Criteria

5.	Participant reports a response of ***"0" (zero)*** on the pain, pressure or discomfort scale (**SYM-Q**, Question #1).	❑$_1$ Yes	❑$_0$ No	❑$_{99}$ N/A
6.	Participant reports no chronic pain in the pelvic or bladder region, and reports **no** chronic pain in **any other body regions**.	❑$_1$ Yes	❑$_0$ No	❑$_{99}$ N/A
7.	Participant reports no urological symptoms that have been evaluated, but are still present.	❑$_1$ Yes	❑$_0$ No	❑$_{99}$ N/A

ALL INCLUSION CRITERIA RESPONSES ABOVE MUST BE "YES" FOR THE CONTROL PARTICIPANT TO BE ELIGIBLE FOR ENROLLMENT IN THE MAPP CONTROLS STUDY.

Trans-MAPP Exclusion Criteria

8.	Participant has an on-going symptomatic urethral stricture.	❑$_1$ Yes	❑$_0$ No
9.	Participant has an on-going neurological disease or disorder affecting the bladder or bowel fistula.	❑$_1$ Yes	❑$_0$ No
10.	Participant has a history of cystitis caused by tuberculosis, radiation therapy or Cytoxan/cyclophosphamide therapy.	❑$_1$ Yes	❑$_0$ No
11.	Participant has augmentation cystoplasty or cystectomy.	❑$_1$ Yes	❑$_0$ No
12.	Participant has an active autoimmune or infectious disorder (such as Crohn's Disease or Ulcerative Colitis, Lupus, Rheumatoid Arthritis, Multiple Sclerosis, or HIV).	❑$_1$ Yes	❑$_0$ No
13.	Participant has a history of cancer (with the exception of skin cancer).	❑$_1$ Yes	❑$_0$ No
14.	Participant has current major psychiatric disorder or other psychiatric or medical issues that would interfere with study participation (e.g. dementia, psychosis, upcoming major surgery, etc).	❑$_1$ Yes	❑$_0$ No
15.	Participant has severe cardiac, pulmonary, renal, or hepatic disease that in the judgment of the study physician would preclude participation in this study.	❑$_1$ Yes	❑$_0$ No

ALL TRANS-MAPP EXCLUSION CRITERIA RESPONSES MUST BE "NO" FOR THE CONTROL PARTICIPANT TO BE ELIGIBLE FOR ENROLLMENT IN THE MAPPII CONTROLS STUDY.

MAPP research network MAPP II SPS	**Participant ID:** __ __ __ __ __ __	**Pin #** __ __ __ __
	Discovery Site: __ __	**Clinical Center** __ __
	CRF Date: __ __/__ __/__ __ __ __	**Visit #:** __ __

MAPP Phase II Eligibility Confirmation for Control Participants

Research Coordinator completes at **Month 0 and Month 6 Screening/Deep Phenotyping** Clinic Contacts.

Exclusion Criteria – Treatment and history

16. Participant has had definitive treatment for acute epididymitis, urethritis, vaginitis. ❑$_1$ Yes ❑$_0$ No
17. Participant has history of unevaluated hematuria. ❑$_1$ Yes ❑$_0$ No
18. Participant has had a cystoscopy with hydrodistention or kenalog injection. ❑$_1$ Yes ❑$_0$ No

ALL TREATMENT AND HISTORY EXCLUSION CRITERIA RESPONSES MUST BE "NO" FOR THE CONTROL PARTICIPANT TO BE ELIGIBLE FOR ENROLLMENT IN THE MAPPII CONTROLS STUDY.

Exclusion Criteria for Males *ONLY*, (Please record 99 – N/A for Females.)

19. Male Participant diagnosed with unilateral orchalgia, without pelvic symptoms. ❑$_1$ Yes ❑$_0$ No ❑$_{99}$ N/A
20. Male Participant has a history of transurethral microwave thermotherapy (TUMT), transurethral needle ablation (TUNA), balloon dilation, prostate cryo-surgery, or laser procedure. ❑$_1$ Yes ❑$_0$ No ❑$_{99}$ N/A
21. Male Participant has had a prostate biopsy or Transurethral Resection of the Prostate (TURP) within the last three months. ❑$_1$ Yes ❑$_0$ No ❑$_{99}$ N/A

Specimen Exclusion Criteria – Urine test results

***Please note, the following section requires that a urine specimen be collected from the Participant in order to assess eligibility via the following procedures (check each box to confirm specimen collected and procedure done):**

Male and Female Participants:

☐ Urine dipstick

☐ Urine culture (Must be documented on Urine Culture Result for Control Pts. – **UCR_CON** form)

Female Participants:

☐ Pregnancy Test

22. Participant has an abnormal dipstick urinalysis, indicating abnormal levels of nitrites and/or occult blood. ❑$_1$ Yes ❑$_0$ No

Question #23 is an Exclusion Criterion for females of childbearing potential *ONLY.*

(Please record 99 - N/A for males and females who are surgically sterile or postmenopausal.)

23. Female participant has a positive urine pregnancy test. (Must be excluded if positive urine pregnancy test.) ❑$_1$ Yes ❑$_0$ No ❑$_{99}$ N/A

MAPP research network MAPP II SPS	**Participant ID:** __ __ __ __ __ __	**Pin #** __ __ __ __
	Discovery Site: __ __	**Clinical Center** __ __
	CRF Date: __ __/__ __/__ __ __ __	**Visit #:** __ __

MAPP Phase II Eligibility Confirmation for Control Participants

Research Coordinator completes at **Month 0 and Month 6 Screening/Deep Phenotyping** Clinic Contacts.

Fatigue Symptom Eligibility Criteria

If the Control Participant has had any of these symptoms for at least **three (3) months in the past year**, please mark the appropriate box.

24. Persistent fatigue not relieved with rest. ❑$_1$ Yes ❑$_0$ No
25. Extreme fatigue following exercise or mild exertion. ❑$_1$ Yes ❑$_0$ No
26. Impaired memory, concentration or attention. ❑$_1$ Yes ❑$_0$ No

ALL RESPONSES FOR FATIGUE/IMPAIRMENT SYMPTOMS LISTED ABOVE MUST BE "NO" FOR THE CONTROL PARTICIPANT TO BE ELIGIBLE FOR ENROLLMENT IN THE MAPPII CONTROLS STUDY.

27. **Did the participant meet all eligibility criteria at this visit?** ❑$_1$ Yes ❑$_0$ No

28. Research Coordinator ID ___ ___ ___ ___ (4-digit ID)